Sign up USA
Proactive Investors - Run By Investors For Investors

Q BioMed announces favourable amendment to debenture financing

The new maturity date has been extended to November 30, 2018
Q BioMed announces favourable amendment to debenture financing
Q BioMed’s CEO, Denis Corin said: “We are pleased that this deal has worked out well for them and us and we will continue to work with them to secure the best outcome for both them and the rest of our shareholders.”

Q BioMed Inc (OTCMKTS:QBIO) said its funding partner, Yorkville Advisors has agreed to extend the maturity date on its US$2mln balance of the convertible note by one year.

The new maturity date has been pushed to November 30, 2018.

READ: Q BioMed says cancer pain drug will be available later this month

On November 29, last year, the biotech acceleration company entered into a securities purchase deal with Yorkville Advisors to place convertible debentures with a one-year term for US$4mln, with a 5% interest.

Q BioMed’s CEO, Dens Corin said: “We are pleased that this deal has worked out well for them and us and we will continue to work with them to secure the best outcome for both them and the rest of our shareholders.”

View full QBIO profile View Profile

Q BioMed Inc Timeline

Related Articles

1504120610_biotechLatest.jpg
August 31 2017
The company is poised for a milestone-rich period over the next year or so
the word antioxidant
August 15 2017
The heparin test is the firm’s lead product; however the company’s OxiChek device for oxidative stress is also gaining traction
Workers at CERN
September 29 2017
The technology being developed is cheaper and smaller than the current units, which are almost prohibitively expensive
Copyright © Proactiveinvestors.com, 2017. All Rights Reserved - Proactive Investors North America Inc., Proactive Investors LLC

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use